ArticleBMJ case reports2020
Sustained clinical response to infliximab in refractory Cronkhite-Canada syndrome.
Article in BMJ case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Vedolizumab as a Second Line Biologic for Cronkhite Canada Syndrome and an Approach Toward Disease Monitoring.ACG case reports journal · 2025Article
- Cronkhite-Canada Syndrome Presenting as Diarrhea and Weight Loss: A Case Report and Literature Review.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Review
- Infliximab treatment for Cronkhite-Canada syndrome in pregnancy: A case report.Case reports in women's health · 2025Article
- Cronkhite-Canada syndrome complicated with pulmonary embolism: A case report.World journal of clinical cases · 2024Article
- Polyposis of gastrointestinal tract after COVID-19 mRNA vaccination: a report of two cases.Clinical endoscopy · 2024Article
- Cronkhite-Canada Syndrome: A Rare Cause of Gastrointestinal Polyposis With Response to Emerging Therapy.ACG case reports journal · 2024Article
- A case report of Cronkhite-Canada syndrome first encounterd at a hospital in northern Vietnam.Annals of medicine and surgery (2012) · 2023Article
- Surgery for Cronkhite-Canada syndrome complicated with intussusception: A case report and review of literature.World journal of gastrointestinal surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 59-year-old man with refractory Cronkhite-Canada syndrome (CCS) had poor clinical response to high-dose intravenous steroids, azathioprine, total parenteral nutrition and best supportive care. He remained highly symptomatic with abdominal pain, diarrhoea, recurrent sepsis and profound weight loss. Infliximab induction was given as rescue therapy, with marked clinical improvement observed within 3 weeks. This allowed steroid taper. Within 12 months of infliximab therapy, he achieved complete clinical remission and returned to his baseline weight and a full oral diet. Sequential endoscopies observed significant regression of previous marked gastrointestinal polyposis, including histological remission on colonic biopsies at 3.5 and 5 years of treatment. He currently remains in remission following 6 years of combination therapy with 5 mg/kg 8 weekly infliximab and azathioprine, and there is ongoing discussion with regard to the benefits and risks of therapy de-escalation. This case demonstrates the effectiveness of infliximab in inducing and maintaining remission in refractory CCS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.